Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

Mauricio Tohen, K. N. Roy Chengappa, Trisha Suppes, Carlos A. Zarate, Joseph R. Calabrese, Charles L. Bowden, Gary S. Sachs, David J. Kupfer, Robert W. Baker, Richard C. Risser, Elisabeth L. Keeter, Peter D. Feldman, Gary D. Tollefson, Alan Breier

Research output: Contribution to journalArticle

379 Citations (Scopus)

Abstract

Background: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. Methods: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients with bipolar disorder (n = 344), manic or mixed episode, who were inadequately responsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy (olanzapine + moodstabilizer) or monotherapy (placebo + mood-stabilizer). Results: Olanzapine cotherapy improved patients' YMRS total scores significantly more than monotherapy (-13.11 vs -9.10; P = .003). Clinical response rates (≥50% improvement on YMRS) were significantly higher with cotherapy (67.7% vs 44.7%; P

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalArchives of General Psychiatry
Volume59
Issue number1
StatePublished - 2002

Fingerprint

olanzapine
Valproic Acid
Bipolar Disorder
Lithium
Placebos
Therapeutics
Randomized Controlled Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. / Tohen, Mauricio; Roy Chengappa, K. N.; Suppes, Trisha; Zarate, Carlos A.; Calabrese, Joseph R.; Bowden, Charles L.; Sachs, Gary S.; Kupfer, David J.; Baker, Robert W.; Risser, Richard C.; Keeter, Elisabeth L.; Feldman, Peter D.; Tollefson, Gary D.; Breier, Alan.

In: Archives of General Psychiatry, Vol. 59, No. 1, 2002, p. 62-69.

Research output: Contribution to journalArticle

Tohen, M, Roy Chengappa, KN, Suppes, T, Zarate, CA, Calabrese, JR, Bowden, CL, Sachs, GS, Kupfer, DJ, Baker, RW, Risser, RC, Keeter, EL, Feldman, PD, Tollefson, GD & Breier, A 2002, 'Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy', Archives of General Psychiatry, vol. 59, no. 1, pp. 62-69.
Tohen, Mauricio ; Roy Chengappa, K. N. ; Suppes, Trisha ; Zarate, Carlos A. ; Calabrese, Joseph R. ; Bowden, Charles L. ; Sachs, Gary S. ; Kupfer, David J. ; Baker, Robert W. ; Risser, Richard C. ; Keeter, Elisabeth L. ; Feldman, Peter D. ; Tollefson, Gary D. ; Breier, Alan. / Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. In: Archives of General Psychiatry. 2002 ; Vol. 59, No. 1. pp. 62-69.
@article{f6bce0e76ccb4fdea11581258a40fcd4,
title = "Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy",
abstract = "Background: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. Methods: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients with bipolar disorder (n = 344), manic or mixed episode, who were inadequately responsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy (olanzapine + moodstabilizer) or monotherapy (placebo + mood-stabilizer). Results: Olanzapine cotherapy improved patients' YMRS total scores significantly more than monotherapy (-13.11 vs -9.10; P = .003). Clinical response rates (≥50{\%} improvement on YMRS) were significantly higher with cotherapy (67.7{\%} vs 44.7{\%}; P",
author = "Mauricio Tohen and {Roy Chengappa}, {K. N.} and Trisha Suppes and Zarate, {Carlos A.} and Calabrese, {Joseph R.} and Bowden, {Charles L.} and Sachs, {Gary S.} and Kupfer, {David J.} and Baker, {Robert W.} and Risser, {Richard C.} and Keeter, {Elisabeth L.} and Feldman, {Peter D.} and Tollefson, {Gary D.} and Alan Breier",
year = "2002",
language = "English (US)",
volume = "59",
pages = "62--69",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

AU - Tohen, Mauricio

AU - Roy Chengappa, K. N.

AU - Suppes, Trisha

AU - Zarate, Carlos A.

AU - Calabrese, Joseph R.

AU - Bowden, Charles L.

AU - Sachs, Gary S.

AU - Kupfer, David J.

AU - Baker, Robert W.

AU - Risser, Richard C.

AU - Keeter, Elisabeth L.

AU - Feldman, Peter D.

AU - Tollefson, Gary D.

AU - Breier, Alan

PY - 2002

Y1 - 2002

N2 - Background: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. Methods: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients with bipolar disorder (n = 344), manic or mixed episode, who were inadequately responsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy (olanzapine + moodstabilizer) or monotherapy (placebo + mood-stabilizer). Results: Olanzapine cotherapy improved patients' YMRS total scores significantly more than monotherapy (-13.11 vs -9.10; P = .003). Clinical response rates (≥50% improvement on YMRS) were significantly higher with cotherapy (67.7% vs 44.7%; P

AB - Background: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes. Methods: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients with bipolar disorder (n = 344), manic or mixed episode, who were inadequately responsive to more than 2 weeks of lithium or valproate therapy, were randomized to receive cotherapy (olanzapine + moodstabilizer) or monotherapy (placebo + mood-stabilizer). Results: Olanzapine cotherapy improved patients' YMRS total scores significantly more than monotherapy (-13.11 vs -9.10; P = .003). Clinical response rates (≥50% improvement on YMRS) were significantly higher with cotherapy (67.7% vs 44.7%; P

UR - http://www.scopus.com/inward/record.url?scp=0036138659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036138659&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 62

EP - 69

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 1

ER -